Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product in a First-in-Human Trial (PALL) in Pediatric Patients with CD19+Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia